CTLA4 and metastatic melanoma: TERT promoter mutations have been discussed as potential prognostic factors in metastatic melanoma [5, 6, 8, 26, 27] and as potentially predictive most recently under BRAF/MEK [7] and anti-CTLA4 therapy [9].